

# Exploration Of Deadly Coronavirus: Epidemiology, Pathophysiology, And Clinical Significance

Vipin Kesharwani<sup>\*1</sup>, <sup>2</sup> Sagarika Kabra<sup>1</sup>, Anuradha Kesharwani<sup>3</sup>, Ayushi Kumari<sup>4</sup>, Mohd Asad Farooqi<sup>5</sup>, Dr. Bhupesh Chandra Semwal<sup>2</sup>

<sup>1</sup>School of Pharmaceutical Sciences, Maharishi University of Information Technology, Lucknow U.P India.

<sup>2</sup>Institute of Pharmaceutical Research, GLA University Mathura, U.P India.

<sup>3</sup> National Institute of Pharmaceutical Education and Research (NIPER), Hajipur. India.

<sup>4</sup>Pranveer Singh Institute of technology, Kanpur U.P India.

<sup>5</sup>Shambhunath Institute of Pharmacy Department of Pharmacology Jhalwa Prayagraj U.P India

---

## ABSTRACT:

The goal of review article is to present a starter assessment against illness of Corona virus; name is derived from the outer fringe or Corona. Corona Virus disease came into existence from December 2019, when Corona virus came into existence in human marine life act Wuhan South China and quickly roll out all over the world. The infection originated in bats and was transmitted to human. Covid has infected humans and cause a large number of respiratory infections including Severe Respiratory Syndrome. It has also various names such as Coronavirus (SARS-CoV), Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Human Coronavirus (HCoV) which has found to cause contamination in respiratory illnesses resulting from acute to chronic distribution. In contrast most recent 15 years, we have seen the rise of two salmonellosis SARS-CoV and MERS-CoV. The Disease Corona Virus (Covid-19) is communicated either by contact or by inhalation of infected droplets of which incubation period ranges from 1 to 2 weeks. In this disease most of the people mild from the symptoms are generally fever, hack, sore throat, windedness, exhaustion etc. The disease can be treated by broad treatment, indicative treatment or by utilizing antiviral medications, O<sub>2</sub> treatment and also by the immune system. It is required to exceptionally recognize the patient and isolate them as soon as possible for conceivable the confirmed cases of Corona virus.

**KEYWORDS:** Covid-19, Symptomatic, Zoonotic, SARS-CoV, MERS-CoV.

---


## INTRODUCTION:

Coronavirus (CoV) is a part of genus Coronavirus of Coronaviridae family. The characteristics of CoV are Pleomorphic Ribo-nucleic acid virus having crown shaped peplomers size range (80-160nm) and positive polarity (27-32 kb). The high pace of blunders is caused due to Recombinant paces of CoVs which has bounced Ribo nucleic acid dependent on RNA polymerase. Due to their high modification rate, they are found to be zoonotic pathogens found in living organisms and has created a wide scope in clinical highlights resulting from asymptomatic course to requirement of hospitals in emergency units,

respiratory diseases, GIT diseases, liver diseases, brain disorders etc.<sup>1-3</sup>This zoonotic infection brought about by serious dreadful respiratory disorder. The COVID-19 disease as said by WHO is irreplaceable illness and named it Novel Covid infected Pneumonia (NCIP) and due to this it is named as 2019 novel Covid (2019-nCoV). On February 11, 2020, the (WHO) formally gave another name the clinical condition Coronavirus (a shortening of Covid Illness 19), which was officially announced as SARS-CoV-2 came into existence in Wuhan, Hubei Region, China in month of Dec. 2019, the present epidemic episode authoritatively a global disaster situation. <sup>4</sup> Since information about this infection is quickly advancing, peruses are urged to refresh themselves consistently (Fig.1). As Said by World wellbeing association (WHO) this disease has a very large group of infections, infecting birds, vertebrates also human beings. It is found that these infections has been accountable for less episodes throughout the globe in contributing with extreme dreadful respiratory condition (SARS) pandemic 2002-2003 with

this the Centre East respiratory disorder (MERS) FALRE UP IN REGIONS OF South Korea during 2015. In contrast as late of, a novel Covid (SARS-CoV-2) also called as Coronavirus has placed an episode in China (December, 2019) spreading global concern all over the planet. As seen in some cases it has caused annihilating infections causing simple to more serious respiratory diseases as equal to normal viruses. In cases of hacking and wheezing the infection is spread quickly from one individual to another by respiratory droplets. It is found that majority of infections are found in individuals who are inductive, in spite of which transmission may be conceivable before manifestations as seen in patients. From starting the side effects begins and continues from two to 14 days, with a normal range of five days. Normal manifestations include pyrexia, hack, wheezing and gasping. The Complications might include pneumonia, throat torment and intense respiratory pain condition. The proposed prophylactic measures include hand cleaning with sanitizers, mouth protect, avoiding others and observing and self-segregation for a couple of 12-14 days in individuals who are found to be infected. <sup>5</sup> In this standard apparatus for analysis done by switch record polymerase chain response (rRT-Polymerase Chain Reaction) from a throat swab or nasopharyngeal swab. The contamination can likewise be analyzed from a mix of indications, hazard factors and a chest Computed Tomography filter showing highlights of pneumonitis.

6



**Figure 1:** A Coronavirus structure respiratory syndrome (SARS)

#### **HISTORY:**

Positive sense ribonucleic acid viruses ranging size from 60 nm-140 nm in width and having projections spike like on its surface that has a crown-like shape when looked through electron microscope are referred to as Covid. <sup>7</sup> Four specific covid viruses, HCoV-HKU1, HCoV-NL63, HCoV-229E, and HCoV-OC43, were available for use in people, and were mostly used to treat mild respiratory disease. In the last two decades, there have been two instances when the hybridization of animal beta Covid with humans has resulted in severe illness. Another occurrence occurred in the Guangdong area of China in 2002–2003, when another Covid of the genus, which began in bats, spread to people through the middle person host of palm civet felines. This illness, classified as a very intense respiratory condition

Covid, affected 8422 people in China and Hong Kong, with 916 of them dying (a mortality rate of 11%) before being contaminated. <sup>8</sup> Around ten years behind, in 2012, the Middle East respiratory disease Covid (Middle East Respiratory Syndrome-CoV), with bat origin, come out in Saudi Arabia with the dromedary camel as the transitional host, attacking 2494 people and causing 858 fatalities (a 34 percent fatality rate). <sup>9</sup>

#### **EPIDEMIOLOGY:**

A large number of pneumonia samples that were grouped in Wuhan city in December 2019 were recorded for, and searches for the main led to Huanan Seafood Market. On December 12, 2019, the first case of the Corona virus pestilence was diagnosed with inexplicable pneumonia, and on December 31, 2019, twenty-seven viral pneumonia cases, seven of which were severe, were publicly announced. <sup>10,11</sup> The medical records of these patients all reveal a history of high-risk interaction, bolstering the

similarities of an illness spreading from animals to people. <sup>3,11</sup> On dated 22 January, 2020, a new Corona virus was identified as having originated in wild bats and was classified as belonging to Group 2 of beta-Covid (SARS-CoV). Despite the fact that corona virus and SARS belong to the same beta Covid subgroup, their genome similarity is only 70%, and the original collection has been discovered to demonstrate hereditary differences from severe acute respiratory disease covid 19. <sup>12</sup> This flare-up, like the severe acute respiratory syndrome pandemic, erupted during China's Spring Festival, the country's most well-known traditional event, during which over 3 billion people travel throughout the country. These circumstances created ideal situations in spreading of this severely infective illness, as well as significant difficulties in avoiding and controlling the epidemic. The Chinese Spring Festival took place between 17 January and 23 February in 2003, when the severe acute respiratory syndrome epidemic was at its peak, and will take place between 10 January and 18 February in 2020. Between 10 and 22 January, there was a high increment in corona virus samples. Wuhan, the pandemic's epicentre with a population of 10 million people, is also a major transit hub for the spring festival. When compared to the number of visitors in 2003, the approximate no. of visitors for the 2020 spring festival has increased by 1.7 times, to 3.11 bn from 1.82 billion. This massive amount of travelling movement has caused ideal circumstances in the development of this difficult-to-control illness. <sup>13</sup>

**Table 1: In No. of Samples and euthanasia in Corona virus breakout as reported by WHO. <sup>11</sup>**


Sr.No	Country	Zone	Cases	Death
1.	China	Asia	42.708	1.017
2.	Singapore	Asia	45	0
3.	Hong Kong	Asia	42	1
4.	Thailand	Asia	33	0
5.	South Korea	Asia	28	0
6.	Japan	Asia	26	0
7.	Malaysia	Asia	18	0
8.	Germany	Europe	16	0
9.	Australia	Australia	15	0
10.	Vietnam	Australia	15	0
11.	United State	North America	13	0
12.	France	Europe	11	0
13.	Macao	Asia	10	0
14.	United Kingdom (UK)	Europe	8	0
15.	United Arab Emirates	Asia	8	0

Death Rate Varies by Age, Sex and Health Conditions:

**Corona virus euthanasia rate/ age group**

Euthanasia Rate = No. of euthanasia/No. of cases = Probability of dying if infected by the virus (%). Numerous examinations progressively evident that passing rate increments with age Children under nine years old appear to be generally unaffected, either with no or gentle manifestations or none have die due to corona virus disease. While individuals beyond 8 years, old years and who are having ongoing


sicknesses are found to be defenseless. In those who cross eighty, around 14.80 percent of people contaminated dies. Below fig. data 2.



**Figure 2:** Corona virus euthanasia rate by various age group

**Corona virus euthanasia rate by sexuality ratio**


Researchers are as yet not totally sure but rather perhaps overall, men more include in wellbeing harming propensities like drinking and smoking than ladies (Figure 3.) Show death sex various. <sup>14</sup>



**Figure 3:** Corona virus euthanasia rate by male and female ratio

**Corona virus euthanasia rate/ health conditions**

Data given by Centers for Disease Control and Prevention (CDC) and loads in subject for different examinations progressively certain that danger of serious sickness and demise increments with age. Among grown-ups age 60 or more established, the greater part additionally has a genuine ailment ascending to almost 66% of individuals' age 80 and more seasoned.<sup>4, 15</sup> In individuals pertaining to heart and blood vessels (coronary illness), passing rate is 10.5 percent, for high blood sugar level demise rate is 7.3 percent, for persistent obstructive pulmonary illness infection (like asthma and ongoing obstructive respiratory sickness) it is 6.3%, for (high blood pressure) is 6.0 percent and malignant tumor passing rate is 5.6 percent information summed up in data<sup>14,16</sup> Fig.4.



**Figure 4:** Corona virus euthanasia rate by Pre existing health Conditions

**PATHOPHYSIOLOGY:**

**Stage 1: Initial State (Asymptomatic State) 1-2 Days of Infection**

The Severe acute respiratory syndrome corona virus is breathed and binds to epithelial cells in the nasal cavity, where it reproduces. The ACE2 receptor is used by both SARS-CoV2 and SARS-CoV1. <sup>17,18</sup> In respect with in vitro experiments with severe acute respiratory syndrome-Corona Virus, the ciliated cells, in which one of the ciliated cells are found to be earliest cells who cause infection in the conducting airways. Though single celled Ribo-nucleic acid shows the conducting airways cells which indicate just a little amount of Angiotensin Converting Enzyme-2, that there is no obvious cell type preference which indicated that we need to update the theory. As seen the virus spreads but there is very little innate immune response. These people are found to be infectious, even when the virus load is low.

The result of viral Ribo Nucleic Acid Reverse Transcriptase -Polymerase Chain Reaction may help in predicting viral load.<sup>19,20</sup>

**Stage 2: Air-Passage Rection in Upper Airway & Airway Passage Response in the Conducting Airway (next few days).**

As the virus moves and spreads inside the respiratory track, this causes a greater innate immune response inside the conducting airways. Nasal consonant or saliva have include the ailment severe acute respiratory syndrome corona

virus as well as initial markers of the innate immune response. COVID-19 is now a clinically visible illness. Levels of CXCL10 (or another innate response cytokine) may be predictive of clinical outcome.<sup>21</sup> Virally infected epithelial cells release high amounts of interferons.<sup>22</sup> In both severe acute respiratory syndrome corona virus & influenza alveolar type II cell responses, CXCL10 is an interferon-responsive gene with a high signal-to-noise ratio.<sup>23,24</sup> C-X-C motif chemokine ligand 10 has also been shown to be a useful alimnet marker in the case of severe acute respiratory syndrome.<sup>21,25</sup>

### Stage 3: Hypoxia, Ground glass infiltrates, and Progression to ARDS

As seen approximately 20percent of infection causing individuals may initiate to 3<sup>rd</sup> degree illness, which has lung infiltrates, with few sick persons having major extreme illness. The mortality rate is initially believed to be approximately 2%, although this differs dramatically according to the age.<sup>26</sup> The mortality & morbidity rates might be adjusted once the prevalence of moderate & asymptomatic ill individuals understood. The virus has now infected type II alveolar cells in the gas exchange units of the lungs. SARS-CoV and influenza preferentially infect type II cells compared to type I cells.<sup>27, 28</sup> Infected alveolar units are usually found in the periphery and subpleural space.<sup>29 30</sup> Before type II cells apoptose and die, SARS-CoV replicates in them, producing a large number of virus particles (figure 1).<sup>23</sup> Infecting type II cells in adjacent units, the released virus particles produce a self-replicating pulmonary toxin. In certain portions of lungs, I predict most type II cells will be lost, and a secondary route for epithelial regeneration will develop. In a mouse influenza pneumonia model, this suggested sequence of events has been demonstrated.<sup>31, 32</sup> SARS and COVID-19 induce widespread alveolar damage, with fibrin-rich hyaline membranes and a few multinucleated big cells.<sup>33, 34</sup> Due to aberrant wound healing, some types of ARDS might result in more severe scarring and fibrosis. A robust intrinsic as well as ACE2 expressing cells will be required for recovery.<sup>35</sup> COVID-19's pathophysiology has significant knowledge gaps so that they can be filled in another months. In my remarks were predicated on the premise that SARS-CoV-2 would enter the body similarly to SARS-CoV. In our knowledge there is not any kind of receptors for entry of virus. CD209L is another receptor for SARS-CoV.<sup>36</sup> In the future, infection and the innate immune response of differentiated primary human lung cells will be investigated in deeper depth. Both type II cells' microvilli and airway cells' apical cilia may play a role in viral entry. Finally, corona virus has conformation in the conducting airways has to be cured symptomatically at home only. On the other hand, Corona virus has uplifted to gas exchange units.

### **SYMPTOMS:**

A study was done on approx 140 patients at Wuhan University's Zhongnan Hospital identified a variety of symptoms that led to the development of COVID-19. Nearly all of the patients developed a fever with an extremely high temperature, while more than half of the patients also experienced fatigue and a dry cough. A dry cough and trouble breathing affected one-third of the patients.<sup>37</sup> According to the Chinese CDC, 80% of COVID-19 infections due to light, patients (15%) developed dreadful cases with 5% of patients are found to be in critical condition. Everyday analysis of COVID-19 manifestants about the condition on how the symptoms develop in typical day to day sick person and how the condition of Corona virus worsens.<sup>37</sup>



**Day 1** The majority of individuals illness condition, 88 %, pyrexia with weary on the first day of symptoms. There's also a lot of pain and a dry cough.

**Day2-4** The body temperature rises with whooping condition.

**Day 5** In continuation with 5<sup>th</sup> day, there will be trouble in breathing. The condition will occur if patient has already condition or older in age.

**Day 6** Respiration problems with rise in body temperature continues, few persons experience chest constriction or the feeling of a band around the chest occurs.

**Day 7** Symptoms like prolonged pain in chest with breathing issues, lips bluish or face should be taken to hospital on the same day as soon as possible.

**Day 8** Around 15 percent of individuals with corona virus suffers manifestations of ADRs, as said by Chinese Center for Disease Control and Prevention.

**Day 10** In hospitals the patients are more likely to be send to the ICU on this day if their breathing problems develop.

**Day 12** In Wuhan research, most people's fevers wear off around 12<sup>th</sup> day. More no of people have the symptoms of whooping.

**Day 13-14** Breathing issues are normally subsiding for people who will survive the infection particularly days.

**Day 18** The people not able to bear the infection, the minimum lifespan of days from starting to end of the infection persists for 18 ½ days.

#### TREATMENT OF COVID-19:

It is important to recall readers about updating clinical characteristics, clinical identification and medication for results of Corona Virus should be updated every hour. However, optimal additional care adds to the cornerstone in treatment, and the clinical efficacy of subsequent medications is currently being researched or tested in clinical studies.<sup>38</sup> Other viruses, such as SARS - Covid 19, MERS,<sup>39</sup> & non-coronaviruses, provide in majority of existing clinical and preclinical data on antiviral therapy (Ebola).<sup>40-</sup>

<sup>42</sup>

#### General Treatment

A verified COVID 19 sick person needs proper bed rest and supportive care, also more calorie & more H<sub>2</sub>O intake to avoid dehydration. Patients should develop H<sub>2</sub>O electrolyte equilibrium & stability, as well as keeping track of vital sight and O<sub>2</sub> saturation; maintaining the respiration path clear and inhaling oxygen in more serious cases; Depending on the patient's condition, blood count, C-reactive protein, urine test, and other blood biochemical indices such as hepatic & renal roles, myocardial enzyme spectrum, and coagulation roles are measured.

#### Symptomatic Treatment

When a patient has a high temperature, it is necessary to take preventative steps. If the fever rises above 38.5 °C, antipyretic medication should be taken. As a prophylactic strategy to reduce the temperature, a patient is given hot tub bath with some antipyretic patches also. Ibuprofen (5–10 mg/kg every period) and acetaminophen (10–15 mg/kg every period) are two common medications. In the event that the infant has convulsions or seizures, a sedative may be required.

#### Oxygen Therapy

As the virus targets the lungs, the odds of hypoxia grow. The patient is subjected to nasal catheter and O<sub>2</sub> masks right away. In an emergency, the patient should be given non-invasive or invasive mechanical ventilation.<sup>43</sup>

### COMPLICATION:

#### Respiratory System Involvement

A distinctive feature of Corona virus is the connection of the system respiration that it produces as substitutional & infection in lungs tissue CT helpful before time identification of covid-19 pneumonia. The computed tomography scans for coronavirus patients shows an diverse marking, extending from single ground-glass opacity to bilateral diffuse heterogeneous consolidation with air bronchogram and bronchiectasis, the 'white lung'. As seen disease progresses, CT scans show partial and double lobular joint. Minor pleural effusion, lymphadenopathy, modified halo sign and pulmonary nodules are frequently outlined in corona virus pneumonitis.<sup>44, 45</sup> In histopathological analysis of COVID-19 severe lung patients, ARDS patterns such as SARS (increased alveolar injury, pneumocyte depletion, hyaline membrane growth, edema and infiltration) are being seen. The Cytopathic contagion effect suggests direct SARSCoV-2 invasion of pneumocytes.<sup>46, 47</sup>

#### Involvement of Renal (kidney)

Acute Kidney Injury is major providing component to corona virus-19 associated mortality.<sup>48</sup> Similarity to Severe Acute Respiratory Syndrome -CoV and Middle East Respiratory Syndrome, the renal system is major target of Corona Virus-19.<sup>49,50</sup> Podocytes and tubular epithelial cells are closely associated with Angiotensin Converting Enzyme -2 receptors, which are divergent earmarks of Severe Acute Respiratory Syndrome -CoV-2.<sup>51</sup>

In a highly focused, retrospective, experimental study at 2 hospitals situated in Wuhan, China, additionally a quarter twenty eight percent of the group emerged Acute Kidney Injury. Proteinuria, hematuria, increased levels of urea N<sub>2</sub> & serum creatinine in the blood as found around the range of 59,44,14 & 10% patients, approximately. Such changes, together with urine & analysis, have been strongly associated with mortality in corona virus infected individuals.<sup>52</sup> In this presence of microalbumin, alpha-1-microglobulin, immunoglobulin-G and transferrin in the urine analysis of 12 patients confirms glomerular and tubular damage in association with corona virus disease.<sup>53</sup> A currently systematic study and meta-analysis communicated that the average occurrence of acute kidney injury in completely corona virus patients was 4.5%. With this, the occurrence of acute kidney injury was 52.9% (95% CI: 34.5-71.4%) and 0.7% (95% CI: -0.3 to 1.8%) in both non-survivors and survivors. Hence, acute kidney injury implants should be jointly related to size & prediction of corona virus patients.<sup>54</sup> Recently explained the pathogenesis of acute kidney injury in association with corona virus. Histo-pathological investigation from COVID-19 kidney tissue examination shows that severe acute respiratory syndrome -

Covid Virus -2 particularly points on kidney tubules (associated with ACE 2 receptors) by extensive proliferation. Dehydration, use of nephrotoxic medications such as NSAIDs, diuretics, ganciclovir and vancomycin, rhabdomyolysis, suffocation, panic attacks and various other diseases (unabandoned high blood sugar level or high blood pressure) which can be caused by AKI during hospitalization. <sup>48</sup>

#### Electrolyte Imbalance

The influence of SARS -Corona virus second on the AC -Angiotensin-II arrangement leads to the prevention of Angiotensin II damage. Portable Angiotensin- II stimulates aldosterone buildup & promotes urinary potassium loss. <sup>55,56</sup> In addition, in sick individuals with major dysentery and/or emesis, external potassium loss may also effect or exacerbate deficiency of potassium in the blood. Hypokalemia is a well-known threat associated in increase of acute respiratory distress syndrome and which tending to produce cardiac arrhythmia. Electrolyte disorder has be show to be consistent with LGL cells counts & corona virus concentration. Hypophosphate was diagnosed in 50 % of serious cases in a small of 20 sick patients. Hypophosphate may be caused by the stress of viral infection and intestinal loss due to impaired mucosal integrity. Maintaining normal serum phosphorus level can help promote respiratory health and improve immune function. <sup>57</sup>

#### Liver Involvement

A combined analysis of 243 patients forms 8 studies, aspartate aminotransferase increase occurs in 20% of corona virus sick person (95 percent CI: 15,3-25.6 percent). Alanine aminotransferase levels are detected in 14.6 percent of corona virus cases (95 percent confidence interval :12.8- 16.6) according to data obtained form six investigation involving 197 sick person. <sup>58</sup> Other studies have shown abnormal aminotransferase (AST &ALT) values in 14-53 percent of coronavirus cases. <sup>59</sup> In 44.4 and 31.59 percent of coronavirus sick person, respectively gammaglutamyltransferase (GT) and lactate dehydrogenase level were likewise increased. <sup>60</sup> At bedtime, elevated levels of alkaline phosphatase (ALP) were seen in one out of every 56 sick person (1.8 percent). <sup>61</sup> Although hepatic enzyme rise is often temporary in moderate cases of the disorder considerable liver enzyme elevation is seen in severe corona virus. Although liver impairment caused by corona virus is not linked to a higher risk of death, sick person with elevated liver enzyme have been shown to spend more time in the hospital. <sup>59</sup> In the majority corona virus sick person, ALP levels were not observed to be increased. Corona virus hepatic damage by a variety of pathways, including direct viral infection via the biliary tract, hypoxia associated with pneumonia, CRS, & drug-induced liver injury caused by lopinavir/ritonavir. <sup>3<sup>rd</sup></sup> individuals who got infected with Severe Acute Respiratory Syndrome-Co had their biopsies done and it was discovered that they had direct hepatocyte viral infection. <sup>62</sup> The infectivity of Sars -CoV in liver is poorly understood (63). DILI, or viral damage, could not be established in a post- mortem biopsy of a liver from a corona virus infected sick person (46). SARS-CoV has been shown to cause liver damage in individuals with hepatitis B/C virus, however the consequence of co-infectious with viral hepatic illness are unknown. <sup>63</sup> Corona virus may have a negative impact on medication metabolism and risk the of toxic drugs. <sup>64</sup>

#### Obstetric & Gynecologic Complications

In considering the threat of intrauterine transmission of corona virus uncertainty exists in this very restrained confirmation indicate that the vertical transmission of corona virus is possible in late pregnancy. <sup>65</sup> Some factors like increased O<sub>2</sub> demand & Physiologic anemia at the time of pregnancy may increase the vulnerability of corona virus. Details of the scientific indications of corona virus on pregnancy are less in number to case reports as well as case series. In keeping view, with review by

seeing a series of cases, the data reported that among 32 pregnant women who got contagious with SARS -CoV-2, 6% need Intensive Care unit supervision. In 47% of sick persons, premature delivery takes place; in which one woman gave birth to a stillborn baby and one birth led to the death of baby.<sup>66</sup> This disease has led to a massive high risk of miscarriage & intrauterine future growth restriction.<sup>67</sup> A study was done on a group of 42 pregnant females, various signs & symptoms mimicking preeclampsia which includes high blood

pressure, proteinuria, high liver enzymes and thrombocytopenia were detected in 14 percent of pregnant females who got infection from severe acute respiratory syndrome -Corona Virus -2.<sup>68</sup>

#### Central Nervous System Involvement

In Excess of 3-quarters (88%) of serious Corona virus patients showed neuronal expressions, including severe cerebral-vascular disease, encephalopathy. In contrast, it is found that patients with Central Nervous System Involvement, the graph of disease was found to be more dreadful and in lymphopenia, higher level of ferritin and LDH level observed.<sup>69</sup> In antecedent explorations it has been confirmed the presence of SARS-CoV in Central Nervous System as found in neuroinvasive characteristic of betacoronavirus. Due to similar structurally and pathogenicity of SARS-CoV(ACE 2 -mediated entry), COVID-19 respiratory and cardiac frailty has been linked with neuroinvasive potency of Severe Acute Respiratory Syndrome Coronavirus2.<sup>70</sup> Pathogenesis, clinical manifestations and problems with the review of COVID-19 Other inputs may emerge from the cribriform plate using the retrograde neuronal pathway, that may be a description of hyposomia.<sup>71</sup> In addition, some strains of the Coronaviridae clan have been shown in spreading by synaptically to the medullary cardio-respiratory center from both mechano-receptors & Chemo-receptors in lungs as well as lower respiratory tract.<sup>70</sup> Acute coronary heart disease is considered a COVID-19 neurologic problem especially in elderly patients, with high blood pressure & atrial fibrillation disorders; even though it may be possible even in junior patients without any threat factor.<sup>72</sup> Some higher evidences suggested that SARS-Co-2 stimulated a prothrombic environment that stimulated activation of endothelial cells, tissue expression, thrombin production and hyper-coagulability. In Elevated D-dimer Levels ( $\geq 1000 \mu\text{g/l}$ ) it is found to have Large-vessel occlusion.<sup>73</sup> The risk of cerebral infarcts could be increased by the presence of antiphospholipid.<sup>74</sup> On March 4 in year 2020, the first discharge was confirmed at Beijing Ditan Hospital in which the virus from CSF of a patient with Corona Virus was observed and reported. In a Latest description, a case of necrotizing encephalopathy which is related to corona virus was reported.<sup>75</sup> In a current record, a case of necrotizing encephalopathy having relation to corona virus was seen. The patient's manifestations include pyrexia, cough and a non-invasive attitude SARS was seen in the nasopharyngeal swabs. The culture of Cerebro Spinal Fluid viruses, viral load tests reports -ve. Unfortunately, the reports for severe acute respiratory syndrome-Corona Virus -2 could not be performed. Infectious CRS caused by a virus as well as blood and brain damage that may be caused by severe bleeding encephalopathy.<sup>76</sup> **DRUGS:** The National Health Commission of the People's Republic of China has determined that drugs such as interferon (IFN-), Lopinavir/Ritonavir, Chloroquine Phosphate, Ribavirin, and Arbidol comes under very helpful medical medications in the prohibition, diagnosis, observation & therapeutically effective in COVID-19 induced inflammation of lungs.

#### **Table -2 NAME OF DRUGS WITH THEIR DOSAGE AND TIME OF DRUG DURATION TREATMENT**

Sr. No	Drug Name	Brand Name	Dose	Route of Administration	Time of Drug Treatment
1.	IFN- alpha	Rebetron	Dose twice a day, each time.	Vapor Inhalant	Not exceeding than 10 days
2.	Ritonavir	Lopimune	200 mg/50 mg/capsule, two capsules twice a day	Pertaining To Mouth	Not exceeding than 10 days
3.	Ribavirin	Rebetol	500 mg each time, 2 to 3 times/ day in combination with IFN - alpha	I.V, Infusion	Not exceeding than 10 days
4.	Chloroquine phosphate	Aablaquin	500 mg (2 times/day)	Pertaining To Mouth	Not exceeding than 10 days
5.	Arbidol	Umifenovir	200 mg each time, 3 times/day	Pertaining To Mouth	Not exceeding than 10 days

- **IFN- $\alpha$**  is given to adults twice a day in the form of steam aspiration ,dose (5 million U ) as well as 2ml sterile water for injection.
- The grown-ups should take 400 mg/100 mg **lopinavir/ritonavir** twice a day.
- Ribavirin should be given to adults as a 500 mg intravenous infusion 2-3 times/day with IFN- or lopinavir/ritonavir.
- **Chloroquine phosphate** as given through mouth administration to adults twice a day with amount of dose 500 mg that is around 300 mg for chloroquine.
- Arbidol is taken three times a day in a dose of 200 mg for adults.
- **Favipiravir** is a novel COVID-19 treatment that is now undergoing clinical trials. China authorised it as a helpful medicine for treating Novel Influenza on February 15, 2020. It works by blocking the RNA-dependent RNA Polymerase enzyme. Apart from anti-influenza virus activity, this medicine also inhibits the replication of flavi-, alpha-, filo-, bunya-, arena-, noro-, and other RNA viruses.
- **Remdesivir** is another investigational medicine being tested in a clinical trial for COVID-19 therapy. Remdesivir is a broad-spectrum antiviral and nucleoside analogue. It significantly reduce viral load in lung tissue of mice infected with MERS-CoV, enhance lung function, & ameliorate pathological damage to lung tissue, according to animal studies.

**Table 3 - Drug in different phase of clinical trials for covid -19**

Drug name	Clinical Trail (Stage)	Active constituents	Mechanism of action	Inventor/ Sponsor	Reference

Ultomiris	Phase III	Rvulizumab-cwvz	C5 complement inhibitor	Alexion Pharmaceutical Inc.	77
MED 13506	Phase II	Interleukin	Decrease cytokine storm	AstraZeneca	78-80
Soliris	Phase II	Eculizumab	Reduce organ damage	Alexion	81-83
Remsima	Phase II	Infliximab	Dampen the hyper-inflammation	Celltrion/University of Oxford/University hospital Birmingham	84-87
Emetine HCl	Phase II/III	Emetine hydrochloride	Inhibiting ribosomal protein synthesis	Acer therapeutics Inc./ national center for advancing translational science	88
DAS181	Phase II/III	Recombinant sialidase	Inhibiting sialic acid binding	Ansun biopharma	89-91
Kaletra, Abbott	Phase III	Lopinavir, Ritonavir	Inhibiting cytochrome P450 enzyme	Hospital of Zhejiang university school medicine/ Hospital of Chongqing medical university	92-99
AT-527	Phase II	Purine nucleotide	Inhibit enzyme RNA polymerase	Atea Pharmaceuticals, Inc	100-101
Virazole	Phase II	Ribavirin	Inhibit virus replication	Bausch Health Americans, Inc	102-104
Favipiravir	Phase III	Favipiravir	Inhibiting RNA-dependent RNA Polymerase	Glenmark Pharmaceuticals	105-112
GS-5734	Phase III	Remdesivir	Inhibit RNA-dependent RNA polymerase	Gilead science	113-115
Prezcobix	Phase III	Darunavir and Cobicistat	Protease inhibitor	Shanghai public health clinical center	116-119
Arbidol	Phase IV	Umifenovir	Inhibit fusion and penetration of the virus into the host cell	Shahidbeheshti university of medical science	120,121

NA-831	Phase III	Neurosivir	Inhibiting RNA-Dependent RNA polymerase	Neuroactive	113-115
Truvada	Phase III	Tenofovir disoproxil and emtricitabine	Reverse transcriptase enzyme inhibitor	PNS	122-124
EIDD-2801	Phase II	Ribonucleoside analog	Inhibiting reproduction of multiple RNA viruses	Ridgeback biotherapeutics	125-127
GC5131A	Phase II	Hyperimmune globulin-based	Enhance immunity	Korean GC Pharma	128,129

**PREVENTION & PRECAUTION OF COVID 19:**

- People should be updated with current COVID-19 epidemic update from the World Health

		therapy			
Gamifant	Phase II/III	Emapalumab	Inactivate interferon-gamma	Swedish orphan biovitrum	130-132
Gimsilumab	Phase II	Gimsilumab	Granulocyte macrophage-colony stimulating factor inhibitor	Roivant science	133-135
REGN-COV2	Phase III	Antibodies combination	Reduce the capacity of transformed viruses to flight the treatment	Regeneron pharmaceuticals Inc.	136-137
Actemra/RoActemra	Phase III	Tocilizumab	Inhibitory effect on IL-6 receptor	Roche	138-139

Organization (WHO) and other sources. Follow your regional sovereignty important instructions to reduce lower-level sickness and man to man communication to your nearby colleagues and Health-care services.

- In this pandemic the people should have a regular habit of washing hands with soap and then water for around 20 seconds, with this you can also use a alcohol based hand sanitizer that contains around 60% of alcohol. After this you should protect your hands and rub them together until they dry completely. Kindly take these precautions if you have wheezing, sneezing or running nose.
- Touching a variety of surfaces exposes hands to the possibility of contracting a virus. These infected hands have the potential to spread the infection to your nose, eyes, and mouth. As a result, do not touch these items with bare handed as virus moves or travel through the human body from there and cause people to become ill.

- People who are sick should be kept at a safe distance (at least one metre or three feet away from you) (who are coughing or sneezing). Coughing or sneezing by infected individuals may lead to drop, globule, vapour transmission of this virus to be expelled from nasal route and oral route and the vapours and drops are breathable. <sup>140-141</sup>
- It is best to stay away from large events and large gatherings of people.
- Workers and halt the spread of the disease on a global scale. Others, however, may suffer from a more severe infection. Take the following steps to protect your health and that of others. <sup>142,140</sup>

Take steps to protect yourself (Steps needed to safeguard other individuals)

- If you are not feeling better then you should not leave the house until it is necessary for medical treatment.
- If you find dryness in mouth, increase in temperature, Respiratory Issues or any kind of medical ailment directly take medical assistance and consult from your doctor in online mode.
- Then, wash hands properly with antiseptic soap immediately afterward.
- During Coughing or Sneezing protect your mouth and nose with tissue paper.
- If at all possible, isolate contact with animals and infected family members so that there is very less spreading of this virus (e.g., sharing a room or vehicle). Those people who come in contact with infected person should wear a surgical mask if unable to do so due to breathing difficulties or other reasons. Caretakers should have facemasks on hand in case they are in short supply.
- Try to avoid sharing household items when you're sick.
- For a certain period of time, you should remain at home and follow your doctor's instructions.
- Suspect cases should be identified and isolated.
- Regularly disinfect frequently touched surfaces by spraying them with a disinfectant such as tables, chairs, washbasins, door handles, washrooms, circuit breakers are all included in this category of equipment. [31-33]
- Use detergent with antiseptic soap and water to clean surfaces before disinfecting.
- Identify possible cases as fast as possible, and segregate them from those who have established cases of Corona virus disease, to stop the spread of this virus infection to other ill patients as well as other peoples who are working around them as health care team, before starting clinical care.
- To prevent or stop the spreading of this infection in other patient and medical assistant, identify potential cases as fast as possible and detach them from authenticated cases of Corona-virus disease.
- Respiratory as well as various body secretions should not be exposed to direct physical contact (including examination and exposure). Moving potentially infectious people to isolation rooms and closing the doors, for example, is one example. Distancing yourself from potentially infectious individuals is especially important in a workplace.
- COVID-19 is unlikely to be present in the majority of patients presenting to community pharmacies. Patients with wheezing, freezing or flu-like indications who does not have Corona virus, incidences of movement or proximity records should be treated according to pharmacy best practices and routine cross-infection risk management.
- Worker safety can be improved by implementing additional engineering and administrative controls to prevent close contact with the sick person.



## CONCLUSION

The new virus eruption has given a danger to China in case of its economically, medically and structures related to public health, as well as that of neighboring countries, particularly its surrounding areas. This can be predicted only when we know how this virus will affect the lives of people in India. In addition, new breakouts of zoonotic contagion with diseases are anticipated to occur. As evidenced by our composition reviews, we have encountered cases in which people with COVID-19 infection has no chest CT complications, which results to subclinical infection that has given positive CT imaging results. To continue it there should be screening of asymptomatic patients in which CT must be determined. An in-depth examination of the existence of any probable. As the number of probable instances of COVID 19 infection climbs, the risk of RT-PCR kits going into crisis may rise as well. As a result, in the lack of Reverse Transcriptase-Polymerase Chain Reaction, chest Computed Tomography is mainly needed to facilitate surgical identification, as evidenced in a current process seen from a sample which came from China and certain areas of planet. As seen in ground-glass and consolidation geographies of COVID-19 lung alterations on CT imaging are comparable to those of SARS. By viewing the number of verified cases and deaths, severe acute respiratory syndrome has a fatality rate of 9.5 percent, with the current new COVID-19 looks to have a mortality rate of roughly 2%. Our work has a number of limitations, including the inability to conduct a thorough examination of prospective prefigurement picturing characteristics which could help in prediction of defective outcomes. Furthermore, it ignores with significance of imaging in accompanying and tracking therapeutical conditions in diseased people. In the face of this, our research carries the summing up of our understanding of the disease in a large area of surroundings than the epicenter flare up in Wuhan. In Completion, it shows Chest X-Ray data around mini no. of ill individuals, which is found to be hidden from the most interdisciplinary studies. Finally, Corona Virus has a major impact on community, and adequate medicaments, disinfectation & societal separation will be helpful to the people.

## ACKNOWLEDGMENTS

The content included in this review is mainly summed up with the help of Dr. Bhupesh Chandra Semwal who has given his great contribution for writing this article and providing the information from vast areas of Corona virus and in continuation Miss Sagarika Kabra has also contributed in writing this article and giving the information of clinical significance and Mr. Nikhil Kushwaha has concluded this article by giving information in the spreading of this disease and its mechanism of action. In this way the article is summarized by providing the knowledge of the prevailing disease by Mr. Vipin Keshwarni of Maharishi School of Pharmaceutical Sciences, Maharishi University of Information Technology, Lucknow.

### Conflict of Interest

The authors of this article declares that there is no conflict of interest in this review article.

## REFERENCES:

1. Woo PC, Huang Y, Lau SK, Yuen KY. (2010) Coronavirus genomics and bioinformatics analysis Viruses. 2; 1804 – 20.
2. Drexler JF, Gloza-Rausch F, Glende J, Corman VM, Muth D, Goettsche M, et al. (2010) Genomic characterization of severe acute respiratory syndrome-related coronavirus in European bats and

- classification of coronaviruses based on partial RNA-dependent RNA polymerase gene sequences. *J Virol* 84;11336–49.
3. Yin Y, Wunderink RG. (2018) MERS, SARS and other coronaviruses as causes of pneumonia. *Respirology* 23;130–7.
  4. Murphy A, and Bell D.J, et al. COVID-19, Radiopaedia. <https://radiopaedia.org/articles/covid-19-2?lang=us>.
  5. Center for disease control and prevention, coronavirus disease. (2019) (COVID-19). <https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html>.
  6. Velavan TP, Meyer CG. (2020) The COVID-19 epidemic. *Trop Med Int Health*. 2527;8–280. doi:10.1111/tmi.13383 <https://pubmed.ncbi.nlm.nih.gov/32052514/>.
  7. Richman DD, Whitley RJ, Hayden FG. (2016) *Clinical Virology*, 4th ed. Washington: ASM Press.
  8. Chan-Yeung M, Xu RH. (2003) SARS: epidemiology *Respirology*.8; S9–14.
  9. Middle East Respiratory Syndrome Coronavirus. Available at (2020) <https://www.who.int/emergencies/mers-cov/en/>.
  10. Imperial College London. Report 2: (2020) estimating the potential total number of novel coronavirus cases in Wuhan City, China. <https://www.imperial.ac.uk/mrc-globalinfectiousdisease-analysis/news--wuhan-coronavirus>.
  11. World Health Organization, 2019-nCoV Situation Report-22 on 12 February, 2020. <https://www.who.int/docs/defaultsource/coronaviruse/situation-reports/>
  12. Gralinski L, Menachery V. Return of the Coronavirus: 2019-nCoV, *Viruses* 2020;12:135. [CrossRef]
  13. Chen Z, Zhang W, Lu Y, et al. (2020) From SARS-CoV to Wuhan 2019-nCoV Outbreak: Similarity of Early Epidemic and Prediction of Future Trends: Cell Press.
  14. Age, Sex, Existing Conditions of COVID-19 Cases and Deaths. <https://www.worldometers.info/coronavirus/coronavirusage-sex-demographics/>.
  15. Koma W, Neuman T, (2020) How Many Adults Are at Risk of Serious Illness If Infected with Coronavirus? March Data Note <http://files.kff.org/attachment/Data-Note-How-Many-Adults-Are-at-Risk-of-Serious-Illness-If-Infected-with-Coronavirus.pdf>
  16. Vally H, The Conversation, La Trobe University. <https://theconversation.com/why-are-older-people-more-at-risk-of-coronavirus-133770>.
  17. Wan Y, Shang J, Graham R, et al. (2020) Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. *J Virol* 94; e00127-20.
  18. Hoffmann M, Kleine-Weber H, Schroeder S, et al. (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell* in press.
  19. Sims AC, Baric RS, Yount B, et al. (2005) Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs. *J Virol* 79; 15511–15524.
  20. Reyfman PA, Walter JM, Joshi N, et al. (2019) Single-cell transcriptomic analysis of human lung provides insights into the pathobiology of pulmonary fibrosis. *Am J Respir Crit Care Med*; 517–1536.

21. Tang NL, Chan PK, Wong CK, et al. (2005) Early enhanced expression of interferon-inducible protein-10 (CXCL-10) and other chemokines predicts adverse outcome in severe acute respiratory syndrome. *Clin Chem* 51; 2333–2340.
22. Hancock AS, Stairiker CJ, Boesteanu AC, et al. (2018) Transcriptome analysis of infected and bystander type 2 alveolar epithelial cells during influenza A virus infection reveals in vivo Wnt pathway downregulation. *J Virol* 92;1325-18.
23. Qian Z, Travanty EA, Oko L, et al. (2013) Innate immune response of human alveolar type II cells infected with severe acute respiratory syndrome-coronavirus. *Am J Respir Cell Mol Biol* 48; 742–748.
24. Wang J, Nikrad MP, Phang T, et al. (2011) Innate immune response to influenza A virus in differentiated human alveolar type II cells. *Am J Respir Cell Mol Biol* 45; 582–591.
25. Rockx B, Baas T, Zornetzer GA, et al. (2009) Early upregulation of acute respiratory distress syndrome-associated cytokines promotes lethal disease in an aged-mouse model of severe acute respiratory syndrome coronavirus infection. *J Virol* 83;7062–7074.
26. Wu Z, McGoogan JM. (2019) Characteristics of and important lessons from the coronavirus disease (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention.in press.
27. Mossel EC, Wang J, Jeffers S, et al. (2008) SARS-CoV replicates in primary human alveolar type II cell cultures but not in type I-like cells. *Virology* 372; 127–135.
28. Weinheimer VK, Becher A, Tonnies M, et al. (2012) Influenza A viruses target type II pneumocytes in the human lung. *J Infect Dis* 206;1685–1694.
29. Wu J, Wu X, Zeng W, et al. (2019) Chest CT findings in patients with corona virus disease and its relationship with clinical features. *Invest Radiol* in press.
30. Zhang S, Li H, Huang S, et al. (2019) High-resolution CT features of 17 cases of corona virus disease in Sichuan province, China. *Eur Respir J* 2020; in press.
31. Kumar PA, Hu Y, Yamamoto Y, et al. (2011) Distal airway stem cells yield alveoli in vitro and during lung regeneration following H1N1 influenza infection. *Cell* 147; 525–538.
32. Yee M, Domm W, Gelein R, et al. (2017) Alternative progenitor lineages regenerate the adult lung depleted of alveolar epithelial type 2 cells. *Am J Respir Cell Mol Biol* 56; 453–464.
33. Gu J, Korteweg C. (2007) Pathology and pathogenesis of severe acute respiratory syndrome. *Am J Pathol* 170 ;1136–1147.
34. Xu Z, Shi L, Wang Y, et al. (2020) Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med* 8; 420–422.
35. Nikolaidis NM, Noel JG, Pitstick LB, et al. (2017) Mitogenic stimulation accelerates influenza-induced mortality by increasing susceptibility of alveolar type II cells to infection. *Proc Natl Acad Sci USA* 114; 6613–6622.
36. Jeffers SA, Tusell SM, Gillim-Ross L, et al. (2004) CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. *Proc Natl Acad Sci USA* 101;15748–15753.
37. Bendix A, A day-by-day breakdown of coronavirus symptoms shows how the disease, COVID-19, goes from bad to worse, *Business Insider* Feb 2020. <https://www.businessinsider.in/science/news/a-day-by-day-breakdown-of-coronavirussymptoms-shows-how-the-disease-covid-19-goes-from-bad-to-worse/articleshow/74257460.cms>

38. Siegel D, Hui HC, Doerffler E, et al. (2017) Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrole [2,1-f ][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. *Journal of medicinal chemistry* 60; 1648-1661.
39. WHOQ&A on coronaviruses (COVID-19). <https://www.who.int/news-room/q-a-detail/q-a-coronaviruses>
40. Erin K. McCreary E.K, and Pogue J.M, COVID-19 Treatment: A Review of Early and Emerging Options, on behalf of the Society of Infectious Diseases Pharmacists. <https://watermark.silverchair.com/>
41. O'Keefe BR, Giomarelli B, Barnard DL, et al. (2010) Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae. *Journal of virology*. 84; 2511-2521.
42. Arabi YM, Shalhoub S, Mandourah Y, et al. (2019) Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*.
43. Zhou S, Wang Y, Zhu T, Xia L. (2020) CT features of Coronavirus Disease (Covid-19) pneumonia in 62 patients in Wuhan, China. *Am. J. Roentgenol*. 214;1287–1294
44. Pan F, Ye T, Sun P et al. (2019) Time course of lung changes at chest CT during recovery from Coronavirus Disease (Covid-19). *Radiology* 295; 715–721.
45. Xu Z, Shi L, Wang Y et al. (2020) Pathological findings of Covid-19 associated with acute respiratory distress syndrome. *Lancet Resp. Med*. 8(4),420–422.
46. Wu C, Chen X, Cai Y et al. (2020) Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Intern. Med*. 180; 1–11.
47. Cheng Y, Luo R, Wang K et al. (2020) Kidney disease is associated with in-hospital death of patients with Covid-19. *Kidney Int*. 97; 829–838.
48. Diao B, Feng Z, Wang C et al. (2020) Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Preprint from MedRxiv. doi: 10.1101/2020.03.04.20031120.
49. Eckerle MM I, Kallies S, Gotthardt DN, Drosten C. (2013) In-vitro renal epithelial cell infection reveals a viral kidney tropism as a potential mechanism for acute renal failure during Middle East Respiratory Syndrome (Mers) coronavirus infection. *Virol. J*. 10(1), 359.
50. Pan X-W, Da Xu, Zhang H, Zhou W, Wang L-H, Cui X-G. (2020) Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis. *Intens. Care Med*. 46; 1114–1116.
51. Li Z, Wu M, Guo J et al. (2020) Caution on kidney dysfunctions of 2019-nCoV patients. Preprint from MedRxiv. doi:10.1101/2020.02.08.20021212.
52. Hong X-W, Chi Z-P, Liu G-Y et al. (2020) Analysis of early renal injury in COVID-19 and diagnostic value of multi-index combined detection. Preprint from MedRxiv. doi:10.1101/2020.03.07.20032599.
53. Yang X, Jin Y, Li R, Zhang Z, Sun R, Chen D. (2020) Prevalence and impact of acute renal impairment on COVID-19: a systematic review and meta-analysis. *J. Crit. Care* 24; 1–8.
54. Pal R, Bhansali A. (2020) COVID-19, diabetes mellitus and ACE 2: the conundrum. *Diabetes Res. Clin. Pract*. 162; 108132.

55. Fang L, Karakiulakis G, Roth M. (2020) Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection *Lancet Resp. Med.* 8;(4).
56. Xue X, Ma J, Zhao Y et al. (2019) Correlation between hypophosphatemia and the severity of Coronavirus Disease 2019 patients. Preprint from MedRxiv. doi:10.1101/2020.03.27.20040816.
57. Parasa S, Desai M, Thoguluva Chandrasekar V et al.(2019) Prevalence of gastrointestinal symptoms and fecal viral shedding in patients with Coronavirus Disease. *JAMA Netw. Open.* 3; E2011335.
58. Wong SH, Lui R, Sung JJ. (2020) Covid-19 and the digestive system. *J. Gastroenterol. Hepatol.* 35(5), 744–748.
59. Zhao D, Yao F, Wang L et al. (2019) A comparative study on the clinical features of Coronavirus (Covid-19) pneumonia with other pneumonias. *Clin. Infect. Dis.* doi:10.1093/Cid/Cia247 (Epub ahead of print).
60. Zhang C, Shi L, Wang F-S. (2020) Liver injury in COVID-19: management and challenges. *Lancet Gastroenterol. Hepatol.* 5(5), 428–430.
61. Chau T-N, Lee K-C, Yao H et al. (2004) Sars-associated viral Hepatitis caused by a novel coronavirus: report of three cases. *Hepatology* 39; 302–310.
62. Xu L, Liu J, Lu M, Yang D, Zheng X. (2020) Liver injury during highly pathogenic human coronavirus infections. *Liver Int.* 40; 998–1004.
63. Rismanbaf A, Zarei S. (2020) Liver and kidney injuries in COVID-19 and their effects on drug therapy; a letter to editor. *Arch. Acad. Emerg. Med.* 8; (1).
64. Fornari F. (2020). Vertical transmission of Covid-19-a systematic review. *J. Paediatr. Child H.* 4, 007–013
65. Mullins E, Evans D, Viner RM, O'brien P, Morris E. (2020) Coronavirus in pregnancy and delivery: rapid review. *Ultrasound Obstet. Gynecol.* (5), 586–592.
66. Panahi L, Amiri M, Pouy S. (2020) Risks of Novel Coronavirus Disease (COVID-19) in pregnancy; a narrative review. *Arch. Acad. Emerg. Med.*8;(1).
67. Mendoza M, Garcia-Ruiz I, Maiz N et al. (2020) Preeclampsia-like syndrome induced by severe Covid-19: a prospective observational study. *BJOG* doi:10.1111/1471-0528.16339 (Epub ahead of print).
68. Mao L, Jin H, Wang M et al. (2019) Neurologic manifestations of hospitalized patients with coronavirus disease in Wuhan, China. *JAMA Neurol.* 77; 683–690.
69. Li YC, Bai WZ, Hashikawa T. (2020) The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. *J. Med. Virol.* 92; 552–555.
70. Baig AM, Khaleeq A, Ali U, Syeda H. (2020) Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host–virus interaction, and proposed neurotropic mechanisms. *ACS Chem. Neurosci.* 11; 995–998.
71. Oxley TJ, Mocco J, Majidi S et al. (2020) Large-vessel stroke as a presenting feature of Covid-19 in the young. *N. Engl. J. Med.* 382; (20).
72. Beyrouti R, Adams ME, Benjamin L et al. (2020) Characteristics of ischaemic stroke associated with COVID-19. *J Neurol. Psych.* 91; 889–891
73. Zhang Y, Xiao M, Zhang S et al. (2020) Coagulopathy and antiphospholipid antibodies in patients with Covid-19. *N. Engl. J. Med.* 382; (17)
74. Sun T, Guan J. (2020) Novel coronavirus and the central nervous system. *Eur. J. Nerol.*

doi:10.1111/ene.14227 (Epub ahead of print).

75. Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. (2020) COVID-19–associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features. *Radiology* 296; E119–E120
76. Alexion Announces Planned Initiation of Pivotal Phase 3 Study of ULTOMIRIS® (Ravulizumab) in ALS; 2020. Available from: <https://www.businesswire.com/news/home/20200114005254/en/alexion-announces-planned-initiation-pivotal-phase-3>. [Last accessed on 2021Apr 27].
77. Brackley P. Two AstraZeneca Molecules to Be Explored as COVID 19 Treatments under Government’s ACCORD Platform, Cambridge; 2020. Available from: <https://www.cambridgeindependent.co.uk/business/two-astrazeneca-molecules-to-be-explored-as-covid-19-treatments-under-government-s-accord-platform-9108658>. [Last accessed on 2021 Apr 27].
78. Cayrol C, Girard JP. (2018) Interleukin-33 (IL-33): A nuclear cytokine from the IL-1 family. *Immunol Rev* 281; 154-68.
79. Kearley J, Silver JS, Sanden C, Liu Z, Berlin AA, White N, et al. (2015) Cigarette smoke silences innate lymphoid cell function and facilitates an exacerbated type I interleukin-33-dependent response to infection. *Immunity* 42;566-79.
80. Diurno F, Numis FG, Porta G, Cirillo F, Maddaluno S, Ragozzino A, et al. (2020) Eculizumab treatment in patients with COVID-19: Preliminary results from real life ASL Napoli 2 Nord experience. *Eur Rev Med Pharmacol Sci* 24; 440-7.
81. Noris M, Benigni A, Remuzzi G. (2020) The case of complement activation in COVID-19 multiorgan impact. *Kidney Int* 98;314-22.
82. Castaneda R. (2021) Alexion to Start Soliris in COVID 19 Phase II Trial in Next Few Days, Source Says; Available from: <https://www.pharmaceutical-technology.com/comment/alexion-to-start-soliris-in-covid-19-phase-ii-trial>.
83. Reinisch W. (2019) A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a Phase 1 open-label randomised controlled trial in patients with active Crohn’s disease. *J Crohns Colitis A* 1103:22.
84. Ben-Horin S. (2020) A novel Subcutaneous Infliximab (CT-P13): 1-Year Results Including Switching Results from Intravenous Infliximab (CT-P13) in Patients with Active Crohn’s Disease and Ulcerative Colitis, Oral Presentation (OP24), Presented at ECCO.
85. Yoo DH, Jaworski J, Matyska-Piekarska E. (2019) A Novel Formulation of CT-P13 (Infliximab Biosimilar) for subcutaneous administration One-Year Results from Part One of a Phase I/III Randomised Controlled Trial in Patients with rheumatoid arthritis, Poster (FRI0128 presented at EULAR.

86. DaeHyun Y, Janusz J, Ewa MP, Svitlana S, Delina I, Agnieszka Z, et al. (2019) A Novel Formulation of CT P13 (Infliximab Biosimilar) for Subcutaneous Administration: 30 Week Results from Part Two of a Phase I/III Randomised Controlled Trial in Patients with rheumatoid arthritis, Poster (FRI0128), Presented at Rheumatoid arthritis – biological DMARDs.
87. Bleasel MD, Peterson GM. (2020) Emetine, ipecac, ipecac alkaloids and analogues as potential antiviral agents for coronaviruses. *Pharmaceuticals (Basel)*13:51.
88. Moss R. (2015) DAS181: A novel host directed approach to prevent and treat virus infections. *J Antivir Antiretrovir* 7:4.
89. Salvatore M, Satlin MJ, Jacobs SE, Jenkins SG, Schuetz AN, Moss RB, et al. (2016) DAS181 for treatment of parainfluenza virus infections in hematopoietic stem cell transplant recipients at a single center. *Biol Blood Marrow Transplant* 22; 957-970.
90. Dhakal B, D'Souza A, Pasquini M, Saber W, Fenske TS, Moss RB, et al. (2016) DAS181 Treatment of severe parainfluenza virus 3 pneumonia in allogeneic hematopoietic stem cell transplant recipients requiring mechanical ventilation. *Case Rep Med* 8503275.
91. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. (2020) A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. *N Engl J Med* 382:1787-99.
92. Osborne V, Davies M, Lane S, Evans A, Denyer J, Dhanda S, et al. (2020) Lopinavir-ritonavir in the treatment of COVID-19: A dynamic systematic benefit-risk assessment. *Drug Saf* 43:809-21.
93. Corrao S, Natoli G, Cacopardo B. (2020) A trial of lopinavir-ritonavir in COVID-19. *N Engl J Med* 382:e68.
94. Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. (2004) Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings. *Thorax* 59; 252-6.
95. Chan KS, Lai ST, Chu CM, Tsui E, Tam CY, Wong MM, et al. (2003) Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: A multicentre retrospective matched cohort study. *Hong Kong Med J* 9; 399-406.
96. Li G, de Clercq E. (2020) Therapeutic options for the 2019 novel Coronavirus (2019-nCoV). *Nat Rev Drug Discov* Kupferschmidt K, Cohen J. Race to find COVID-19 treatments accelerates. *Science* 367;1412-3.
97. Lythgoe MP, Middleton P. (2020) Ongoing clinical trials for the management of the COVID-19 pandemic. *Trends Pharmacol Sci* 41:363-82.
98. Good SS, Westover JB, Jung KH, La Colla P. (2020) AT 527 is a Potent In vitro Replication Inhibitor of SARS CoV 2, the Virus Responsible for the COVID 19 Pandemic, *BioRxiv* 242832.
99. Berliba E, Bogus M, Vanhoutte F, Berghmans PJ, Good SS, Moussa A, et al. (2019) Safety, pharmacokinetics, and antiviral activity of AT-527, a novel purine nucleotide prodrug, in hepatitis c virus-infected subjects with or without cirrhosis. *Antimicrob Agents Chemother* 63; 1201-19

100. Yu WC, Hui DS, Chan-Yeung M. (2004) Antiviral agents and corticosteroids in the treatment of severe acute respiratory syndrome (SARS). *Thorax* 59; 643-5.
101. Tan EL, Ooi EE, Lin CY, Tan HC, Ling AE, Lim B, et al. (2004) Inhibition of SARS Coronavirus infection in vitro with clinically approved antiviral drugs. *Emerg Infect Dis* 10; 581-6.
102. Saijo M, Morikawa S, Fukushi S, Mizutani T, Hasegawa H, Nagata N, et al. (2005) Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated Coronavirus. *Antiviral Res* 66;159-63.
103. Yamamura H, Matsuura H, Nakagawa J, Fukuoka H, Domi H, Chujoh S. (2020) Effect of favipiravir and an anti-inflammatory strategy for COVID-19. *Crit Care* 24; 413.
104. Seneviratne SL, Abeysuriya V, de Mel S, de Zoysa I, Niloofa R. (2020) Favipiravir in COVID-19. *Int J Prog Sci Tech* 19143-5.
105. Coomes EA, Haghbayan H. (2020) Favipiravir, an antiviral for COVID-19? *J Antimicrob Chemother* 75;2013-4.
106. Arab Zozani M, Hassanipour S, Ghoddoosi Nejad D. (2020) Favipiravir for Treating Novel Coronavirus (COVID 19) Patients: Protocol for a Systematic Review and Meta Analysis of Controlled Trials, Research Square.
107. Xian Q, Minghui C, Dongjing Y, Jun L, Dan C, Junxia S, et al. (2020) Experimental treatment with favipiravir for COVID 19: An open label control study. *Engineering* 6;1192-1198. [doi: 10.1016/j.eng. 2020.03.007].
108. Syed SJ, Basheeruddin M, Mohammed A, Al-Yamani J. (2020) Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review. *J Infect Public Health* 13;1187-95.
109. Munir MA, Kuganda H, Basry A. (2020) The efficacy and safety of antivirus drugs for COVID-19: A systematic review. *Syst Rev Pharm* 11; 162-6.
110. Sheahan TP, Sims AC, Zhou S, Graham RL, Hill CS, Leist SR, et al. (2020) An orally bioavailable broad spectrum antiviral inhibits SARS CoV 2 and multiple endemic, epidemic and bat Coronavirus. *Sci Transl Med*.997890. [doi: 10.1101/2020.03.19.997890].
111. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. (2020) Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. *Lancet* 395;1569-78.
112. Frediansyaha A, Nainuc F, Dhamad K, Mudatsire M, Harapan H. (2021) Remdesivir and its antiviral activity against COVID-19: A systematic review. *Clin Epidemiol Glob Health* 9;123-7.
113. Saha A, Sharma AR, Bhattacharya M, Sharma G, Lee SS, Chakraborty C. (2020) Probable molecular mechanism of remdesivir for the treatment of COVID-19: Need to know more. *Arch Med Res* 51;585-6.
114. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. (2019) Pharmacologic treatments for coronavirus disease (COVID-19) a review. *JAMA* 2020;323:1824-36.



115. Naveed M, Uddin S, Abdullah KS, Ishaq SE, Ahmad T. (2020) Various evidence-based hypothetical and experimental treatment approaches and their effectiveness against COVID-19 worldwide: A comprehensive literature review. *Eurasian J Med Oncol* 4;265-85.
116. De meyer S, Bojkova D, Cinatl J, van Damme E, Buyck C, van Loock M, et al. (2020) Lack of antiviral activity of darunavir against SARS-CoV-2. *Int J Infect Dis* 97;7-10.
117. Halder UC. (2020) Predicted antiviral drugs darunavir, indinavir and rimantadine can potentially bind to neutralize COVID 19 conserved proteins. *J Biol Res (Thessalon)* [doi: 10.21203/rs.3.rs22247/v1].
118. Lian N, Xie H, Lin S, Huang J, Zhao J, Lin Q. (2020) Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: A retrospective study. *Clin Microbiol Infect* 26; 917-21.
119. Huang D, Yu H, Wang T, Yang H, Yao R, Liang Z. (2019) Efficacy and safety of umifenovir for coronavirus disease (COVID-19): A systematic review and meta-analysis. *J Med Virol* 93;481-90.
120. Vellingiri B, Jayaramayya K, Laxmilyer M, Narayanasamy A, Govindasamy V, Giridharan B, et al. (2020) COVID-19: A promising cure for the global panic. *Sci Total Environ* 725;139277.
121. Chi BH, Sinkala M, Mbewe F, Cantrell RA, Kruse G, Chintu N, et al. (2007) Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: An open-label randomised trial. *Lancet* 370;1698-705.
122. Clososki GC, Soldi RA, da Silva RM, Guaratini T, Lopes JN, Pereira PR, et al. (2020) Tenofovir disoproxil fumarate: New chemical developments and encouraging in vitro biological results for SARS-CoV-2. *J Braz Chem Soc* 31;1552-6.
123. Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML, et al. (2020) An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple Coronaviruses in mice. *Sci Transl Med* 212; 5883.
124. Jarvis LM. (2020) Emory-discovered antiviral is poised for COVID-19 clinical trials. *Org Synth*;98.
125. Toots M, Yoon JJ, Hart M, Natchus MG, Painter GR, Plemper RK. (2020) Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model. *Transl Res* 218;16-28.
126. Han Soo L. (2020) GC Applies for P2 Trials of Plasma Therapy for COVID 19, Korea Biomedical Review; Available from: <http://www.koreabiomed.com/news/articleview.html> [Last accessed on 2021\ Apr 27].
127. Cha S. (2021) South Korea's Green Cross seeks phase two trials of COVID 19 Plasma Drug, the Thomson Reuters Trust Principles; 2020. Available from: <https://in.reuters.com/article/us-health-coronavirus-south-korea-green-cr/south-koreas-green-cross-seeks-phase-two-trials-of-covid-19-plasma-drug-idinkcn24u1j6>.

128. Potì F, Pozzoli C, Adami M, Poli E, Costa LG.(2020) Treatments for COVID-19: Emerging drugs against the Coronavirus. *Acta Biomed* 91;118-36.
129. Chibber P, Haq SA, Ahmed I, Andrabi NI, Singh G. (2020) Advances in the possible treatment of COVID-19: A review. *Eur J Pharmacol* 883:173372.
130. Uckun FM.(2020) Reducing the fatality rate of COVID-19 by applying clinical insights from immuno-oncology and lung transplantation. *Front Pharmacol* 11; 796.
131. Harky A, Mishra V, Ansari DM, Melamed N. (2021) Are open-source approaches the most efficient way forward for COVID-19 drug discovery? *Expert Opin Drug Discov* 16; 115-7.
132. Vijayvargiya P, Garrigos ZE, Almeida NE, Gurram PR, Stevens RW, Razonable RR. (2020) Treatment considerations for COVID-19: A critical review of the evidence (or Lack Thereof). *Mayo Clin Proc* 95;1454-66.
133. Bonaventura A, Vecchié A, Wang TS, Lee E, Cremer PC, Carey B, et al. (2020) Targeting GM-CSF in COVID-19 pneumonia: Rationale and strategie. *Front Immunol* 11;1625.
134. Baum A, Copin R, Ajithdoss D, Zhou A, Lanza K, Negron N, et al.(2021) REGN COV2 Antibody Cocktail Prevents and Treats SARS CoV 2 Infection in Rhesus Macaques and Hamsters; 2020. Available from: <https://www.biorxiv.org/content>. [Last accessed on 2021 Apr 27].
135. Robertson S. (2021) Regeneron's Antibody Cocktail Shows Promise as Potential COVID 19 Treatment; 2020. Available from: <https://www.news medical.net/news/20200805/regenerons covid 19 antibody-drug cocktail treats sars cov 2 virus in animals.aspx>. [Last accessed on 2021 Apr 27].
136. Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, et al. (2020)Tocilizumab in patients with severe COVID-19: A retrospective cohort study. *Lancet Rheumatol* 2020;2:e474-84.
137. Alzghari SK, Acuña VS. (2020) Supportive treatment with tocilizumab for COVID-19: A systematic review. *J Clin Virol* 127;104380.
138. Cortegiani A, Ippolito M, Greco M, Granone V, Protti A, Gregoretti C, et al. (2021) Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. *Pulmonology* 27; 52-66.
139. WHO coronavirus disease 2019 (Covid 2019) situation report- 53, march 2020\_ <https://www.who.int/docs/default-souces/coronavirus/situation-report/2020313-sitrep-53-covid-19.Pdf/sfvr sn=adb3f72>.
140. WHO coronavirus disease (COVID-19) advice for the public\_ <https://www.who.int/emergencies/disease/novel-coronavirus-2019/advice-for-public>
141. How to protect yourself, coronavirus disease 2019 (COVID-Coronavirus Disease 2019 (COVID-19), Center for disease control and prevention. <https://www.cdc.gov/cornavirus/2019-ncov/prepare/prevention.html>
- 142.COVID-19, Occupational safety and Health administration, Unitessssssssd state Department of labour, <https://www.osha.gov/SLTC/covid-19/controlprevention.html>